Literature DB >> 23251003

Breast cancer stem cells: we've got them surrounded.

Hasan Korkaya1, Max S Wicha.   

Abstract

Breast cancer stem cells are regulated by cell intrinsic pathways as well as by elements in the tumor microenvironment. New evidence suggests that an important interaction between the interleukin (IL)-8 receptor CXCR1/2 and HER2 is involved in this regulation. Simultaneous targeting of these pathways provides a novel therapeutic approach.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23251003      PMCID： PMC6276109          DOI： 10.1158/1078-0432.CCR-12-3450

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

Authors:  H Korkaya; A Paulson; F Iovino; M S Wicha
Journal:  Oncogene       Date:  2008-06-30       Impact factor: 9.867

2.  An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.

Authors:  Dimitrios Iliopoulos; Heather A Hirsch; Kevin Struhl
Journal:  Cell       Date:  2009-10-29       Impact factor: 41.582

3.  Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

Authors:  Hasan Korkaya; Gwang-Il Kim; April Davis; Fayaz Malik; N Lynn Henry; Suthinee Ithimakin; Ahmed A Quraishi; Nader Tawakkol; Rosemarie D'Angelo; Amanda K Paulson; Susan Chung; Tahra Luther; Hayley J Paholak; Suling Liu; Khaled A Hassan; Qin Zen; Shawn G Clouthier; Max S Wicha
Journal:  Mol Cell       Date:  2012-07-19       Impact factor: 17.970

Review 4.  Breast cancer stem cells, cytokine networks, and the tumor microenvironment.

Authors:  Hasan Korkaya; Suling Liu; Max S Wicha
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

5.  Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.

Authors:  Ina H Benoy; Roberto Salgado; Peter Van Dam; Katrien Geboers; Eric Van Marck; Simon Scharpé; Peter B Vermeulen; Luc Y Dirix
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.

Authors:  Christophe Ginestier; Suling Liu; Mark E Diebel; Hasan Korkaya; Ming Luo; Marty Brown; Julien Wicinski; Olivier Cabaud; Emmanuelle Charafe-Jauffret; Daniel Birnbaum; Jun-Lin Guan; Gabriela Dontu; Max S Wicha
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

8.  Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.

Authors:  Alessandra Magnifico; Luisa Albano; Stefano Campaner; Domenico Delia; Fabio Castiglioni; Patrizia Gasparini; Gabriella Sozzi; Enrico Fontanella; Sylvie Menard; Elda Tagliabue
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.

Authors:  Jagdeep K Singh; Gillian Farnie; Nigel J Bundred; Bruno M Simões; Amrita Shergill; Göran Landberg; Sacha J Howell; Robert B Clarke
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

10.  Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.

Authors:  Nicola Aceto; Stephan Duss; Gwen MacDonald; Dominique S Meyer; Tim-C Roloff; Nancy E Hynes; Mohamed Bentires-Alj
Journal:  Breast Cancer Res       Date:  2012-10-12       Impact factor: 6.466
View more
  18 in total

1.  Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation.

Authors:  Oshrat Attar-Schneider; Victoria Zismanov; Liat Drucker; Maya Gottfried
Journal:  Tumour Biol       Date:  2015-10-30

2.  Personalised cancer care: promises and challenges of targeted therapy.

Authors:  Shi-Ming Tu; Mehmet A Bilen; Nizar M Tannir
Journal:  J R Soc Med       Date:  2016-03-01       Impact factor: 5.344

Review 3.  Cancer stem cells: a systems biology view of their role in prognosis and therapy.

Authors:  Susan D Mertins
Journal:  Anticancer Drugs       Date:  2014-04       Impact factor: 2.248

4.  Heterogeneity of chemokine cell-surface receptor expression in triple-negative breast cancer.

Authors:  Kerri-Ann Norton; Aleksander S Popel; Niranjan B Pandey
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 5.  How many etiological subtypes of breast cancer: two, three, four, or more?

Authors:  William F Anderson; Philip S Rosenberg; Aleix Prat; Charles M Perou; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2014-08-12       Impact factor: 13.506

6.  HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation.

Authors:  Junying Sun; Baocun Sun; Dongwang Zhu; Xiulan Zhao; Yanhui Zhang; Xueyi Dong; Na Che; Jing Li; Fang Liu; Nan Zhao; Danfang Zhang; Tieju Liu; Xian Lin
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

7.  Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans.

Authors:  Archana Kamalakar; Manali S Bendre; Charity L Washam; Tristan W Fowler; Adam Carver; Joshua D Dilley; John W Bracey; Nisreen S Akel; Aaron G Margulies; Robert A Skinner; Frances L Swain; William R Hogue; Corey O Montgomery; Parshawn Lahiji; Jacqueline J Maher; Kim E Leitzel; Suhail M Ali; Alan Lipton; Richard W Nicholas; Dana Gaddy; Larry J Suva
Journal:  Bone       Date:  2014-01-28       Impact factor: 4.398

8.  Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.

Authors:  Ada Koschorke; Simona Faraci; Debora Giani; Claudia Chiodoni; Egidio Iorio; Rossella Canese; Mario P Colombo; Alessia Lamolinara; Manuela Iezzi; Michael Ladomery; Claudio Vernieri; Filippo de Braud; Massimo Di Nicola; Elda Tagliabue; Lorenzo Castagnoli; Serenella M Pupa
Journal:  Cell Oncol (Dordr)       Date:  2019-08-02       Impact factor: 6.730

9.  Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.

Authors:  Xin Chen; Qiuhui Li; Xin Liu; Can Liu; Ruifang Liu; Kiera Rycaj; Dingxiao Zhang; Bigang Liu; Collene Jeter; Tammy Calhoun-Davis; Kevin Lin; Yue Lu; Hsueh-Ping Chao; Jianjun Shen; Dean G Tang
Journal:  Clin Cancer Res       Date:  2016-04-08       Impact factor: 12.531

Review 10.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.